 Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine SAV. Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus COVID-19 infection. Initiation of the first animal study for the vaccine candidates is expected to begin in May 2020. 